Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery.  Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation.  Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.

Dr. Brody’s research receives funding from numerous grantors, including the National Institutes of Health, the Cancer Research Institute, the Damon Runyon Cancer Research Foundation, and the Lymphoma Research Foundation. He is a member of many professional organizations, including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology.

Dr. Brody is committed to partnering with his patients to choose the most appropriate treatment approach that offers the best outcomes with excellent quality of life.

Learn more about Dr. Brody's research at The Brody Lab.

Dr. Brody is on Twitter at @joshuabrodyMD